

North County Neurology Associates/
The Research Center of Southern California, LLC
6010 Hidden Valley Road, Suite 200.
Carlsbad, California 92011
Phone: 760-732-0557
Fax: 760-732-0358



Gregory Aram Sahagian, M.D.

EDUCATION

Columbia University
School of Engineering and Applied Science, New York City, NY ■ 1991
B.S. in Chemical Engineering

Albert Einstein College of Medicine, Bronx, NY ■ 1995
M.D.

Winthrop University Hospital
SUNY School of Medicine, Mineola, NY ■ 1995-1996
Internship, Medical

University of California, San Diego, San Diego, CA ■ 1996-1998
Residency, Neurology

University of California, San Diego, San Diego, CA ■ 1998-1999
Chief Resident, Neurology

University of California, San Diego, San Diego, CA ■ 1999-2000
Fellowship, Neuromuscular Diseases

LICENSURE

- California Medical License Number – A62263
-
-

PUBLICATIONS

Lindsay Olson-Mack, Jessica Burley, Robin Calara, Robert Claycomb, Linda Coutts, Mary A Kalafut, K. Jill Libby, Renee Richetts, **Gregory Sahagian**, Jean M Rockwell, Scripps Health, San Diego, CA
Who Are We Missing? False Call Rates Decline for Stroke Code Activations During Early Phase of Covid-19 Pandemic Abstract poster ISC meeting 2021

Phillips G, Muppidi S, **Sahagian G**, Smith G, Huang, D, Campbell D; Conceptualization and Novel Budget Impact Analysis Framework for Treatments of Myasthenia Gravis. Abstract ISPOR 2021

- Smith N, Howard J, **Sahagian G**, Smith G, Silvestri NJ, Hehir M, Leighton T, Jeyakumar S, Phillips GA; Comparative Effectiveness and Safety of Efgartigimod in Generalized Myasthenia Gravis Abstract ISPOR 2021
- Wagner, G., Rosen, J., Vignisson, V., **Sahagian, G.**, Haase-Alasantro, L.; A pilot study investigating a voice recognition cognitive screening tool for detection of neuropsychological changes; Abstract AAIC 2021
- Wagner, G., Rosen, J., Holguin, G., Frishberg, B., Wang, A., **Sahagian, G.**, Haase-Alasantro, L. (2016). Clinical Assessment of Posterior Cortical Atrophy. Poster presented at the National Academy of Neuropsychology Conference, Seattle, WA.
- Salloway S, Sperling R, Fox NC, Blennow K, Klunk W, Raskind M, Sabbagh M, Honig LS, Porsteinsson AP, Ferris S, Reichert M, Ketter N, Nejadnik B, Guenzler V, Miloslavsky M, Wang D, Lu Y, Lull J, Tudor IC, Liu E, Grundman M, Yuen E, Black R, Brashear HR; Bapineuzumab 301 and 302 Clinical Trial Investigators. Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease. *N Engl J Med.* 2014 Jan 23;370(4):322-33
- Liu E, Schmidt ME, Margolin R, Sperling R, Koeppe R, Mason NS, Klunk WE, Mathis CA, Salloway S, Fox NC, Hill DL, Les AS, Collins P, Gregg KM, Di J, Lu Y, Tudor IC, Wyman BT, Booth K, Broome S, Yuen E, Grundman M, Brashear HR; Bapineuzumab 301 and 302 Clinical Trial Investigators. Amyloid- β 11C-PiB-PET imaging results from 2 randomized bapineuzumab phase 3 AD trials *Neurology.* 2015 Aug 25;85(8):692-700
- Morello CM, Leckband SG, Stoner CP, Moorhouse DF, **Sahagian GA**: Randomized double-blind study comparing the efficacy of gabapentin with amitriptyline on diabetic peripheral neuropathy pain. *Arch Intern Med* 1999 Sep 13; 159(16): 1931-7